236 related articles for article (PubMed ID: 32599363)
1. A Pt(IV)-based mononitro-naphthalimide conjugate with minimized side-effects targeting DNA damage response via a dual-DNA-damage approach to overcome cisplatin resistance.
Li Y; Yue K; Li L; Niu J; Liu H; Ma J; Xie S
Bioorg Chem; 2020 Aug; 101():104011. PubMed ID: 32599363
[TBL] [Abstract][Full Text] [Related]
2. A potent aminonaphthalimide platinum(IV) complex with effective antitumor activities in vitro and in vivo displaying dual DNA damage effects on tumor cells.
Wang Q; Chen Y; Li G; Zhao Y; Liu Z; Zhang R; Liu M; Li D; Han J
Bioorg Med Chem Lett; 2019 Oct; 29(20):126670. PubMed ID: 31500997
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Cytotoxicity and Reactivity of a Novel Platinum(IV) Family with DNA-Targeting Naphthalimide Ligands.
Navas F; Mendes F; Santos I; Navarro-Ranninger C; Cabrera S; Quiroga AG
Inorg Chem; 2017 Jun; 56(11):6175-6183. PubMed ID: 28488859
[TBL] [Abstract][Full Text] [Related]
4. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
5. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
Wang Z; Xu Z; Zhu G
Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
[TBL] [Abstract][Full Text] [Related]
6. Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.
Cetraz M; Sen V; Schoch S; Streule K; Golubev V; Hartwig A; Köberle B
Arch Toxicol; 2017 Feb; 91(2):785-797. PubMed ID: 27307157
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of a new series of low toxic naphthalimide platinum(IV) antitumor complexes with dual DNA damage mechanism.
Wang Q; Tan X; Liu Z; Li G; Zhang R; Wei J; Wang S; Li D; Wang B; Han J
Eur J Pharm Sci; 2018 Nov; 124():127-136. PubMed ID: 30153524
[TBL] [Abstract][Full Text] [Related]
8. Hybrid of DNA-targeting Chlorambucil with Pt(IV) Species to Reverse Drug Resistance.
Chen F; Xu G; Qin X; Jin X; Gou S
J Pharmacol Exp Ther; 2017 Nov; 363(2):221-239. PubMed ID: 28916659
[TBL] [Abstract][Full Text] [Related]
9. Bromocoumarinplatin, targeting simultaneously mitochondria and nuclei with p53 apoptosis pathway to overcome cisplatin resistance.
Ma J; Li L; Yue K; Li Y; Liu H; Wang PG; Wang C; Wang J; Luo W; Xie S
Bioorg Chem; 2020 Jun; 99():103768. PubMed ID: 32217375
[TBL] [Abstract][Full Text] [Related]
10. Dual-targeting tumor cells hybrids derived from Pt(IV) species and NF-κB inhibitors enables cancer therapy through mitochondrial dysfunction and ER stress and overcomes cisplatin resistance.
Wang M; Li G; Jiang G; Cai J; Zhong W; Huang R; Liu Z; Huang X; Wang H
Eur J Med Chem; 2024 Feb; 266():116095. PubMed ID: 38215589
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
12. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
Chen H; Wang X; Gou S
J Inorg Biochem; 2019 Apr; 193():133-142. PubMed ID: 30731264
[TBL] [Abstract][Full Text] [Related]
13. A naphthalimide-polyamine conjugate preferentially accumulates in hepatic carcinoma metastases as a lysosome-targeted antimetastatic agent.
Ma J; Li L; Yue K; Zhang Z; Su S; Chen Y; Yu L; Zhang P; Ma R; Li Y; Ma Y; Jia H; Wang C; Wang J; Xie S
Eur J Med Chem; 2021 Oct; 221():113469. PubMed ID: 33965862
[TBL] [Abstract][Full Text] [Related]
14. Anticancer Effects of a New Aminosugar-conjugated Platinum Complex Agent Against Cisplatin-resistant Gastric Cancer.
Hayashi N; Kataoka H; Yano S; Kikuchi JI; Tanaka M; Nishie H; Kinoshita Y; Hatano M; Nomoto A; Ogawa A; Inoue M; Mizoshita T; Shimura T; Mori Y; Kubota E; Tanida S; Joh T
Anticancer Res; 2016 Nov; 36(11):6005-6009. PubMed ID: 27793927
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, antitumor activity, and chemical properties of silaplatin and related platinum (II) and platinum (IV) complexes derived from beta-silyl amines.
Anderson WK; Kasliwal R; Houston DM; Wang YS; Narayanan VL; Haugwitz RD; Plowman J
J Med Chem; 1995 Sep; 38(19):3789-97. PubMed ID: 7562909
[TBL] [Abstract][Full Text] [Related]
16. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
17. Enhancing Cytotoxicity of a Monofunctional Platinum Complex via a Dual-DNA-Damage Approach.
Guo Y; He Y; Wu S; Zhang S; Song D; Zhu Z; Guo Z; Wang X
Inorg Chem; 2019 Oct; 58(19):13150-13160. PubMed ID: 31539237
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, Cytotoxicity, and Mechanistic Investigation of Platinum(IV) Anticancer Complexes Conjugated with Poly(ADP-ribose) Polymerase Inhibitors.
Xu Z; Li C; Zhou Q; Deng Z; Tong Z; Tse MK; Zhu G
Inorg Chem; 2019 Dec; 58(23):16279-16291. PubMed ID: 31738050
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and antitumor evaluation of new 1,8-naphthalimide derivatives targeting nuclear DNA.
Liang GB; Wei JH; Jiang H; Huang RZ; Qin JT; Wang HL; Wang HS; Zhang Y
Eur J Med Chem; 2021 Jan; 210():112951. PubMed ID: 33109400
[TBL] [Abstract][Full Text] [Related]
20. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
